New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
17:00 EDTBDSI, ENDPBDSI updates Phase lll clinical trials for BEMA Buprenorphine
BDSI said in a press release that significant progress was made in the development of BioDelivery Sciences International, BDSI's (BDSI), two buprenorphine-containing products with the initiation, in partnership with Endo Health Solutions (ENDP) of two Phase 3 pivotal trials with BEMA Buprenorphine for the treatment of chronic pain. BDSI also completed key bioavailability and safety studies with BUNAVAIL (formerly BEMA Buprenorphine/Naloxone or BNX) for the treatment of opioid dependence. Phase 3 clinical trials for BEMA Buprenorphine in conjunction with Endo to complete in late 2013 or early 2014
News For BDSI;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 20, 2015
08:09 EDTENDPBioSpecifics announces approval of Xiaflex in Japan
Subscribe for More Information
July 17, 2015
10:05 EDTENDPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:38 EDTENDPLeerink puts 25% odds on Teva, Mylan deal within 12 months
Subscribe for More Information
06:43 EDTENDPEndo upgraded to Top Pick from Outperform at RBC Capital
Subscribe for More Information
July 16, 2015
11:36 EDTBDSIBioDelivery Sciences management to meet with FBR Capital
Meetings to be held in Minneapolis on July 22 and in Dallas on July 23 hosted by FBR Capital.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use